You are here

Article Text

Article menu
Download PDFPDF
Letter
Regarding minimal clinically relevant differences for superiority margins
  1. Patrick S Phelan
  1. Washington University School of Medicine, Saint Louis, Missouri, USA
  1. Correspondence to Patrick S Phelan, Washington University School of Medicine, Saint Louis, MO 63110, USA; psphelan{at}wustl.edu

http://dx.doi.org/10.1136/bmjebm-2018-110925

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Being familiar with the relevant previous work of authors Shafiq and Malhotra, I read with interest their recent letter with Gamad concerning reporting of the Canakinumab Anti-Inflammatory Thrombosis Outcome Study (CANTOS).1 That trials such as CANTOS continue to be reported with claims of superiority without consideration of asymmetry in error margins …

    View Full Text

    Footnotes

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; internally peer reviewed.